Tim Boreham Dr Boreham’s Crucible: Don’t have a heart attack, CSL’s profit-making ability is in the blood February 19, 2024 CSL may have bled this week, but our Mr In Between view is that a steady flow of new products… CRITERION: Dumped these education stocks lately? That’ll lern ya. February 17, 2024 Education stocks are looking smart. I *clap* don't *clap* want *clap* to *clap* have *clap* to *clap* tell *clap* you… CRITERION: Thinking of risking a finger on a falling knife? Sometimes they come back… February 10, 2024 While there’s no firm rule, the shares of established, profitable entities tend to recover – and sometimes quickly. Dr Boreham’s Crucible: ResMed holders breathe easy – those fat-busting needles have only hurt a little bit February 5, 2024 If it's true fat pills are a tailwind rather than a threat, ResMed’s nine per cent share sell down after… CRITERION: When is a disaster not a disaster? February 3, 2024 Who had "Bureau of Meteorology gets its wrong" on their bingo card? Oh wait... everybody did. Here's why a bet… CRITERION: Uranium’s got that healthy glow… but here’s why you need to handle it with care January 27, 2024 It's tempting to put all your glowing eggs into the uranium basket right now, but Morgan Stanley is warning of… CRITERION: Three small caps that tick three boxes for a boom ’24 January 20, 2024 Despite the parlous geopolitical climate, market watchers are heralding the volatile and higher-risk small cap sector as the ‘it’ investment… Tim Boreham’s 12 of the best ASX small caps for 2024 January 2, 2024 Following hours of due diligence with shady broker types at Melbourne’s legendary Mitre Tavern, here are our wild stabs at… Dr Boreham’s End-of-Year ASX Biotech report card December 27, 2023 If the biotech sector were a classroom, 2023 would be "patchy but solid effort in trying conditions". And with the… CRITERION: Missed the Pro Medicus boat? These cheaper alternatives scan well December 23, 2023 Have investors in one of Australia’s most dazzling home-grown ASX success stories missed the boat? No. Not really. CRITERION: Missed the Sigma M&A boat? There’s a prescription for that… December 18, 2023 An overlooked, ASX-listed alternative is the trans-Tasman EBOS Group (ASX:EBO), valued at $NZ7 billion. Dr Boreham’s Crucible: Excessive sweater? Botanix is here to get you fit for public consumption again December 12, 2023 Caused by physiological rather than psychological factors, excessive sweating normally becomes apparent in youths aged 12 to 17 years. CRITERION: At Stawell, gold is the gift that keeps on giving December 9, 2023 The Stawell Zone has produced more than five million ounces since the 1850s, mainly from the Stawell Gold Mine at… CRITERION: Can these fast food stocks supersize profits as competition mounts? December 3, 2023 The fast food sector’s reliability is reflected in the dominant position of private equity players in the byzantine ownership structures. Dr Boreham’s Crucible: Can the magic acronyms ‘AI’ and ‘FDA’ see Optiscan probe new heights in 2024? November 27, 2023 Optiscan has developed a hand-held pen-like device for digital biopsies that harnesses confocal laser endo-microscopy to produce hi-res images. CRITERION: Looking for retail therapy this festive season? Remember, cheap isn’t always cheerful November 25, 2023 The outperformance of High Street jewellery over fast fashion highlights the danger of generalisations about consumer behaviour in adverse conditions. CRITERION: It’s a pool party as private equity splashes cash on small cap financial advisors November 18, 2023 “Everyone is trying to find their right partner to dance with.” The sleepy small-cap financial advisory sector is ditching its… Next» « Previous